Dr. Sherman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
149 Sidney Street
Acceleron Pharma
Cambridge, MA 02139Phone+1 617-576-2220
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1983 - 1987
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1980 - 1983
Geisel School of Medicine at DartmouthClass of 1980
Certifications & Licensure
MA State Medical License 1983 - 2026
ME State Medical License Active through 2006- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 740 citationsRandomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell c...Michael B. Atkins, Manuel Hidalgo, Walter M. Stadler, T. Logan, Janice P. Dutcher
Journal of Clinical Oncology. 2004-03-01 - 637 citationsEfficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First RelapseEric L. Sievers, Richard A. Larson, Edward A. Stadtmauer, Elihu H. Estey, Bob Löwenberg
Journal of Clinical Oncology. 2001-07-01 - 301 citationsLuspatercept in Patients with Lower-Risk Myelodysplastic SyndromesPierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti, Guillermo Garcia-Manero, Rena Buckstein
The New England Journal of Medicine. 2020-01-08
Press Mentions
Deciphera Announces First Patient Treated in Phase 1 Study of DCC-3116 in Patients with Advanced or Metastatic Tumors with a Mutant RAS or RAF GeneJune 30th, 2021
Deciphera Pharmaceuticals, Inc. To Present Data from DCC-3014 and Ripretinib Programs at the Connective Tissue Oncology Society (CTOS) 2019 Annual MeetingNovember 13th, 2019- Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2019 Financial ResultsNovember 4th, 2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
